Reduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors.
Reduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors.
Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD.
Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia.
Reduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia.
Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH).
Reduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy.